About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Empagliflozin/Linagliptin/Metformin HCl

Company: Humanis Saglık Anonim Sirketi
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 14, 2026

Trial details

Completed NCT NCT03259490

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Not yet reported Boehringer Ingelheim 30 participants Est. completion 2017-11-13 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Active, not recruiting NCT NCT05220917

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 site

Type 2 diabetes Other conditions: Cardiovascular Events, Renal Disease
View official trial listing →
Completed NCT NCT07213895

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets

Not yet reported Humanis Saglık Anonim Sirketi 14 participants Est. completion 2025-09-18 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT07691203

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets

Not yet reported Humanis Saglık Anonim Sirketi 36 participants Est. completion 2026-07-01 1 site Stand-alone

Type 2 diabetesCardiovascular disease
View official trial listing →
Completed NCT NCT07872358

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets

Not yet reported Humanis Saglık Anonim Sirketi 36 participants Est. completion 2026-10-07 1 site Stand-alone

Type 2 diabetesCardiovascular disease
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT07872358

Also known as: Empagliflozin/Linagliptin/Metformin HCl, Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.